References
- WHO. Cardiovascular disease; 2015 [cited 2015 Mar 27]. Available from: http://www.who.int/cardiovascular_diseases/en/.
- The Pharmaprojects Database, Informa UK Plc; [cited 2016 Jan]. Available from: http://www.pharmaprojects.com.
- Thomson Reuters Integrity, Thomson Reuters Canada Plc; [cited 2016 Jun]. Available from: https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_home.util_home.
- Takeda. × . Pipeline; 2010 [cited 2016 Jan 28]. Available from: http://www.takeda.com/investor-information/results/pdf/2010/qr2010_full_d10_en.pdf.
- Takeda. III. Pipeline1; 2015 Oct 30 [cited 2016 Jan 28]. Available from: http://www.takeda.com/research/files/pipeline_20151030_en.pdf.
- Athersys. MultiStem programs; [cited 2016 Feb 5]. Available from: http://www.athersys.com/msOverview.cfm.
- Athersys. Athersys receives orphan drug designation for multiStem in graft vs. host disease; 2010 Sep 21 [cited 2016 Feb 5]. Available from: http://www.athersys.com/releasedetail.cfm?releaseid=509426.
- Athersys. Athersys’ multistem(R) stem cell therapy receives orphan drug designation in europe for prevention of graft-versus-host disease; 2013 Dec 17 [cited 2016 Feb 5]. Available from: http://www.athersys.com/releasedetail.cfm?ReleaseID=814256.
- Biospace. Athersys, Inc. Receives orphan drug designation for multistem in Hurler’s syndrome; 2012 Jul 10 [cited 5 Feb 2016]. Available from: http://www.biospace.com/news_story.aspx?StoryID=266251&full=1.
- Athersys. Healios and Athersys enter into regenerative medicine partnership for treatment of stroke using multistem(R) Therapy; 2016 Jan 08 [cited 2016 Feb 6]. Available from: http://www.athersys.com/releasedetail.cfm?ReleaseID=949491.
- Athersys. Athersys Announces Positive Results from Phase I Study of Multistem(R) in Heart Attack Patients; 2010 Jul 28 [cited 2016 Jan 30]. Available from: http://files.shareholder.com/downloads/ATHERSYS/1428250267x0x391025/16B0D9E5-ECB6-4204-8EA5-C01227422673/ATHX_News_2010_7_28_General_Releases.pdf.
- Athersys. Athersys announces results from phase 2 study of multistem(R) cell therapy for treatment of ischemic stroke; 2015 Apr 17 [cited 2016 Feb 6]. Available from: http://www.athersys.com/releasedetail.cfm?ReleaseID=907107.
- Athersys. Athersys reports third quarter 2015 results; 2015 Nov 5 [cited 2016 Feb 6]. Available from: http://www.athersys.com/releasedetail.cfm?ReleaseID=941050.
- Athersys. Other programs; [cited 2016 Feb 6]. Available from: http://www.athersys.com/msOtherPrograms.cfm.
- Pfizer, Athersys, Inc. A study to investigate the safety and possible clinical benefit of multistem(r) in patients with moderate to severe ulcerative colitis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2016 Feb 9]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01240915?term=Multistem%28R%29&rank=1NLM Identifier: NCT01240915.
- Pfizer. Pfizer pipeline; 2015 Jul 28 [cited 2016 Jan 30]. Available from: http://120.52.72.39/www.pfizer.com/c3pr90ntcsf0/sites/default/files/product-pipeline/July%2028%202015%20Pipeline%20Update.pdf.
- Mendel I, Feige E, Yacov N, et al. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014;175:126–137.
- Vascular Biogenics. Findings demonstrate potential therapeutic applicability of VB-201 in Atherosclerosis and Other Inflammatory disorders; 2013 Jul 08 [cited 2016 Feb 12]. Available from: http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=1942813.
- Vascular Biogenics. Inflammatory pipeline; [cited 2016 Feb 12]. Available from: http://www.vblrx.com/inflammatory-disease-programs/inflammatory-pipline/.
- VBL Therapeutics. VBL therapeutics presents positive phase 2 data for VB-201 in psoriasis and atherosclerosis at the late-breaking abstract session of the American Academy of Dermatology 70th annual meeting; 2012 Mar 16 [cited 2016 Feb 12]. Available from: http://www.vblrx.com/vbl-therapeutics-presents-positive-phase-2-data-for-vb-201-in-psoriasis-and-atherosclerosis-at-the-late-breaking-abstract-session-of-the-american-academy-of-dermatology-70th-annual-meeting/.
- VBL Therapeutics. VBL therapeutics reports topline results from phase 2 studies of VB-201 in psoriasis and ulcerative colitis; 2015 Feb 17 [cited 2016 Feb 12]. Available from: http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2017105.
- Cision. Interim report. 1 Jan. 2013 till 31 Mar. 2013; [cited 2016 Mar 5]. Available from: http://mb.cision.com/Main/6574/9419623/126426.pdf.
- Business wire. Neurovive pharmaceutical: topline result of phase III study of Ciclomulsion® in acute myocardial infarction expected this quarter; 2015 May 25 [cited 2016 Apr 29]. Available from: http://www.businesswire.com/news/home/20150524005054/en/Neurovive-Pharmaceutical-Topline-Result-Phase-III-Study.
- FierceBiotech. Neurovive pharmaceutical: neurovive refocuses CicloMulsion development – discontinues acute myocardial infarction indication; [cited 2016 Mar 5]. Available from: http://www.fiercebiotech.com/press-releases/neurovive-pharmaceutical-neurovive-refocuses-ciclomulsion-development-disco.
- Inoue E, Ichiki T, Takeda K, et al. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. J Endocrinol. 2012;213:285–291.
- Astellas. Financial results for 1Q/FY2015; [cited 2016 Feb 29]. Available from: http://www.astellas.com/en/ir/library/pdf/1q2016_pre_en.pdf.
- Shire. Study published in The New England journal of medicine demonstrates efficacy and favourable safety profile of Firazyr® (Icatibant) for the treatment of Hereditary Angioedema (HAE) attacks; 2010 Aug 4 [cited 2016 Feb 29]. Available from: https://www.shire.com/newsroom/2010/august/study-published-in-the.
- Shire. Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects; 2013 Nov 11 [cited 2016 Feb 29]. Available from: https://www.shire.com/~/media/shire/shireglobal/shirecom/pdffiles/newsroom/2013/november/20131111-shiretoacquireviropharmarelease11.pdf.
- Shire. Study of icatibant in japanese subjects with acute attacks of HAE; [cited 2016 Mar 4]. Available from: http://www.shiretrials.com/sitecore/content/studies/clinicaltrialsen/2015/05/14/06/44/shp-fir-301?sc_lang=en.
- Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011;52:2169–2176.
- Lilly. Lilly 2012-13 corporate responsibility report; [cited 2016 Feb 22]. Available from: https://www.lilly.com/_Assets/pdf/Lilly_2012_2013_CRreport.pdf.
- Eli Lilly and Company. A study of evacetrapib in high-risk vascular disease (ACCELERATE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2016 Feb 23]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01687998?term=NCT01687998&rank=1 NLM Identifier: NCT01687998.
- Eli Lilly and Company. A study of evacetrapib (LY2484595) in participants with high cholesterol (ACCENTUATE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2016 Feb 22]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02227784 NLM Identifier: NCT02227784.
- Lilly. Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease; 2015 Oct 12 [cited 2016 Feb 22]. Available from: https://investor.lilly.com/releasedetail.cfm?releaseid=936130.
- Zhao HP, Xiang BR. Discontinued cardiovascular drugs in 2013 and 2014. Expert Opin Investig Drugs. 2015;24:1083–1092.
- Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2012: cardiovascular drugs. Expert Opin Investig Drugs. 2013;22:1437–1451.
- Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs. 2012;21:1449–1462.
- Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol. 2009;24:364–371.
- Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES investigators; Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
- Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91:109–122.
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–716.
- Bailey J, Thew M, Balls M. Predicting human drug toxicity and safety via animal tests: can any one species predict drug toxicity in any other, and do monkeys help? Altern Lab Anim. 2015;43:393–403.
- Sugiyma Y, Yamashita S. Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev. 2011;63:494–502.
- Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov. 2008;7:197–198.